Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP vs ESWT for Greater Trochanter Pain Syndrome
NCT03774251Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of platelet-rich plasma in greater trochanteric pain syndrome (GTPS) (2 arms), sponsored by Stanford University. Primary endpoints: Visual Analog Scale for Pain at 12 months, International Hip Outcome Tool at 12 months and 1 more. Planned start Oct 2019; status: withdrawn.
02
Drugs
platelet-rich plasma
03
Conditions
greater trochanteric pain syndrome (GTPS)
Beyond the preview
Go deeper on NCT03774251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774251.